CRSP (CRISPR Therapeutics AG) 3-Month Share Buyback Ratio : -0.72% (As of Mar. 2025 )

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. CRISPR Therapeutics AG's current 3-Month Share Buyback Ratio was -0.72%.

Competitive Comparison of CRISPR Therapeutics AG's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, CRISPR Therapeutics AG's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

CRISPR Therapeutics AG 3-Month Share Buyback Ratio Calculation

CRISPR Therapeutics AG's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Dec. 2024 )
	=	(85.742	-	86.361)	/	85.742
	=	-0.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG (NAS:CRSP) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

CRISPR Therapeutics AG 3-Month Share Buyback Ratio Related Terms

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

CRSP:Mexico 0VRQ:UK 1CG:Germany

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Executives

Raju Prasad	officer: Chief Financial Officer	CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Samarth Kulkarni	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
James R. Kasinger	officer: General Counsel and Secretary	C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
John Greene	director	51 LIME STREET, LONDON X0 EC3M 7DQ
Phuong Khanh Morrow	officer: Chief Medical Officer	C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith	officer: Chief Financial Officer	29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek	officer: Chief Financial Officer	28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak	director, officer: Chief Executive Officer	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming	director	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein	officer: Chief Business Officer	C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
Tony W Ho	officer: See Remarks	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni	director	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080